Overview

Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai

Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
A study to evaluate the efficacy and safety of maralixibat in infants with Biliary Atresia (BA) after Hepatoportoenterostomy (HPE, also known as the Kasai procedure).
Phase:
Phase 2
Details
Lead Sponsor:
Mirum Pharmaceuticals, Inc.